3
Announcements
Trials
Browse
Landscape
Status
Unknown
1
Completed
1
Sponsor Class
OTHER
2
Study Type
Observational
2
Sponsor
Cancer Type
Tumor-Agnostic
1
Conditions
Neoplasms
2
Heart Diseases
1
Cardiotoxicity
1
Interventions
Surveys and Questionnaires
86
Blood Specimen Collection
58
Interviews as Topic
28
Observation
15
Data Collection
15
Radiotherapy
12
Watchful Waiting
11
Magnetic Resonance Spectroscopy
11
Hematologic Tests
11
Exercise
11
Drug Therapy
11
Quality of Life
9
Biopsy
8
Specimen Handling
7
Therapeutics
6
Restraint, Physical
6
Magnetic Resonance Imaging
6
Focus Groups
6
pembrolizumab
5
Standard of Care
5
Rivaroxaban
5
Phlebotomy
5
Nivolumab
5
Lapatinib
5
Immune Checkpoint Inhibitors
5
atezolizumab
4
apixaban
4
Trastuzumab
4
Patient Reported Outcome Measures
4
Palliative Care
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Observational
×
Neoplasms
×
Immunomodulating Agents
×
Clear all
NCT03530215
2023-04-13
EROCA
Groupe Hospitalier Pitie-Salpetriere
Completed
500,000 enrolled
NCT04696250
2021-01-06
AVATAR
University Hospital, Caen
Unknown
5,000,000 enrolled